DNA Synthesis Market to Witness Robust Growth Driven by Biotech Innovations - Persistence Market Research

The global osteoarthritis treatment market continues to evolve rapidly, driven by the convergence of clinical innovation, increasing disease burden, and the demand for more effective and sustainable therapies. Valued at US$ 9.8 billion in 2025, the market is projected to reach US$ 15.3 billion by 2032, registering a compound annual growth rate (CAGR) of 6.6% during the forecast period. This steady growth underscores the expanding need for both pharmacological and surgical interventions that can provide long-term relief and improve quality of life for patients suffering from osteoarthritis (OA)-a condition that remains one of the leading causes of disability worldwide.

The growing prevalence of osteoarthritis, driven by aging populations, obesity, and sedentary lifestyles, is reshaping healthcare priorities globally. Knee osteoarthritis remains the leading indication segment, supported by its high incidence across both developed and developing nations. Meanwhile, North America holds the largest regional share (40.2%), thanks to advanced healthcare infrastructure, robust reimbursement systems, and a strong presence of key pharmaceutical and medical device manufacturers. Conversely, the Asia Pacific region is emerging as the fastest-growing market, powered by healthcare modernization, greater public awareness, and increased investment in regenerative and orthopedic care solutions.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/33942

Key Highlights from the Report

• Global market size valued at US$ 9.8 billion in 2025, expected to reach US$ 15.3 billion by 2032.
• North America dominates the market with a 40.2% revenue share.
• Asia Pacific is the fastest-growing regional market at a 23.4% revenue share in 2024.
• Knee osteoarthritis remains the leading indication segment worldwide.
• Hospitals are the primary end-user segment, driving advanced treatment delivery.
• The European Project on Osteoarthritis (EPOSA) supports regional policy planning and disease impact assessment.

Market Segmentation

The osteoarthritis treatment market is segmented across several critical parameters, including treatment type, indication, and end-user, each influencing demand dynamics and innovation trends.

By Treatment Type

Pharmacological therapies dominate the global osteoarthritis treatment market, accounting for approximately 63.7% of total revenue in 2025. This segment's leadership reflects the widespread reliance on drug-based interventions-ranging from nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids to viscosupplements and emerging biologics. These treatments are preferred due to their affordability, ease of access, and ability to provide immediate symptomatic relief. Furthermore, ongoing R&D in disease-modifying osteoarthritis drugs (DMOADs) and extended-release formulations is expected to redefine long-term management paradigms by addressing the underlying causes of joint degradation rather than simply alleviating pain.

By Indication

The knee osteoarthritis segment leads the global market, representing 44.6% of total market share in 2025. This dominance is attributed to the high global incidence of knee OA, particularly among older adults and individuals with obesity or repetitive joint strain. Increasing adoption of viscosupplementation therapies, corticosteroid injections, and total knee replacement procedures continues to sustain growth in this segment. Meanwhile, hip osteoarthritis represents the fastest-growing indication, driven by improvements in prosthetic design, rising life expectancy, and the growing number of minimally invasive joint replacement surgeries worldwide.

By End-use

Hospitals remain the largest end-user segment, capturing 43.6% of market share in 2025. This leadership reflects the comprehensive orthopedic care and advanced diagnostic infrastructure available within hospital settings, where multidisciplinary teams of orthopedic surgeons, physiotherapists, and rehabilitation experts provide integrated treatment solutions. Increasing numbers of outpatient joint replacement surgeries, coupled with favorable insurance and reimbursement frameworks, further solidify hospitals' dominance. Ambulatory surgical centers and specialty orthopedic clinics are also expanding their footprint, catering to patients seeking cost-effective and minimally invasive interventions.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/dna-synthesis-market.asp

Regional Insights
North America

North America remains the undisputed leader in the osteoarthritis treatment market, holding 40.2% of global revenue in 2025. The region's growth is propelled by the high prevalence of osteoarthritis-affecting nearly one-quarter of U.S. adults-alongside strong healthcare infrastructure, early adoption of regenerative therapies, and widespread availability of surgical solutions. Advanced reimbursement frameworks and high awareness among both clinicians and patients further enhance market accessibility. The strong presence of leading industry players such as Johnson & Johnson, Pfizer, and Zimmer Biomet supports continued innovation in both pharmacological and surgical treatments.

Europe

Europe's osteoarthritis treatment market demonstrates steady expansion, underpinned by demographic aging, increased disease awareness, and government support for early diagnosis and intervention. The continent benefits from strong regulatory oversight and reimbursement support, fostering patient access to innovative drugs and implants. Notably, the European Project on Osteoarthritis (EPOSA) provides comprehensive insights into the personal and socioeconomic impacts of OA, facilitating evidence-based healthcare planning across major economies such as Germany, the U.K., France, and Italy. The growing adoption of regenerative therapies and minimally invasive orthopedic procedures continues to enhance patient outcomes and reduce recovery times.

Asia Pacific

The Asia Pacific region is forecasted to register the highest growth rate (CAGR ~23.4%) through 2032. Expanding geriatric populations in China, Japan, and India-coupled with rising obesity rates-are significantly elevating OA prevalence. Improving healthcare access, technological advancement, and medical tourism are catalyzing the regional market. Countries like India, Thailand, and South Korea are becoming global destinations for affordable and high-quality orthopedic surgeries. Furthermore, domestic manufacturers are investing in cost-efficient implants, viscosupplementation products, and AI-driven diagnostic platforms, strengthening local competitiveness and accessibility.

Market Drivers

Several powerful drivers are shaping the osteoarthritis treatment market's growth trajectory. Foremost is the rising global prevalence of osteoarthritis, linked to demographic aging, lifestyle changes, and obesity. The disease increasingly affects younger and middle-aged individuals, expanding the potential patient base and heightening demand for both preventive and restorative care.

Technological and therapeutic innovations further reinforce market momentum. Breakthroughs in regenerative medicine, stem cell therapy, and biologics are moving the industry beyond symptomatic management toward structural joint repair and disease modification. The development of DMOADs, 3D-printed implants, and AI-assisted diagnostics is revolutionizing how osteoarthritis is detected and treated. Together, these innovations improve precision, reduce recovery time, and enhance long-term patient outcomes.

Additionally, a growing preference for minimally invasive surgeries, coupled with increased healthcare spending and global collaborations between pharmaceutical and medical device companies, continues to propel the market forward.

Market Restraints

Despite strong growth potential, several factors constrain the osteoarthritis treatment market. The high cost of advanced therapies-including biologics, regenerative treatments, and total joint replacements-remains a significant barrier, especially in low- and middle-income regions where healthcare affordability is limited. Inadequate insurance coverage and high out-of-pocket expenses deter patient uptake of premium interventions, shifting preference toward conservative, low-cost management such as analgesics and physiotherapy.

Moreover, uncertainty surrounding the long-term efficacy of regenerative and disease-modifying therapies has hindered widespread adoption. While early clinical results are promising, the absence of large-scale randomized trials demonstrating durable outcomes has created skepticism among clinicians and payers. These limitations restrict patient access to cutting-edge solutions and slow the commercialization of next-generation OA therapeutics.

Market Opportunities

Opportunities in the osteoarthritis treatment market are expanding rapidly with the commercialization of regenerative and disease-modifying therapies. Advances in tissue-engineered products, cell-based implants, and 3D-bioprinted cartilage scaffolds offer the potential to restore joint function and slow disease progression. These approaches are particularly valuable for younger or early-stage OA patients who are not yet candidates for joint replacement. The convergence of biotech innovation and orthopedic engineering is fostering strategic collaborations and accelerating regulatory approvals for these transformative solutions.

The emergence of DMOADs such as lorecivivint (SM04690) and sprifermin (FGF18) represents another critical opportunity. By targeting the molecular pathways responsible for cartilage breakdown and inflammation, these drugs have the potential to redefine osteoarthritis management entirely. If successfully commercialized, they would establish a new therapeutic class that addresses the root cause of OA and provides durable, long-term efficacy-significantly reducing the global disease burden.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/33942

Company Insights

The global osteoarthritis treatment market is highly competitive, with a blend of multinational pharmaceutical giants and specialized biotechnology firms shaping its landscape. Companies are investing heavily in R&D, digital transformation, and patient-centric care models to maintain market leadership.

Key Players Operating in the Market:

• ABIOGEN PHARMA S.p.A
• Assertio Holdings, Inc.
• Abbott
• Bayer AG
• Johnson & Johnson
• Merck KGaA
• Viatris Inc.
• Eli Lilly and Company
• Pfizer Inc.
• Reckitt Benckiser Group PLC
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet
• Apotex Inc.
• Samil Pharmaceutical Co., Ltd.
• Others

DNA Synthesis Market Research Segmentation

By Service Type:

Oligonucleotide
Universal Oligonucleotide
Custom Oligonucleotide
Gene
Custom Gene
Gene Library

By Application:

Research and Development
Academic Applications
Industrial Applications
Diagnosis
Therapeutics

By End User:

Biopharmaceutical Companies
Academic and Research Institutes
Contract Research Organizations

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

These companies are strengthening their product pipelines through mergers, acquisitions, and licensing agreements, while simultaneously investing in advanced pharmacological formulations and regenerative medicine solutions. Strategic initiatives also focus on leveraging real-world data, digital monitoring tools, and AI-powered platforms to enhance treatment personalization and outcome tracking.

Recent Developments:

July 2025 - Johnson & Johnson MedTech partnered with Pacira BioSciences to co-promote ZILRETTA, an extended-release injectable for knee osteoarthritis pain. This collaboration broadens J&J's early-intervention portfolio and expands educational initiatives around non-surgical care options.

September 2024 - Sun Pharma and Moebius Medical received U.S. FDA Fast Track Designation for MM-II, a novel non-opioid therapy targeting knee OA pain. This milestone accelerates regulatory review and enhances treatment access for patients with unmet needs.

Conclusion

The global osteoarthritis treatment market stands at a transformative juncture, transitioning from symptomatic relief toward disease modification and joint regeneration. With market valuation expected to grow from US$ 9.8 billion in 2025 to US$ 15.3 billion by 2032, the industry's trajectory is shaped by clinical innovation, strategic collaborations, and rising patient awareness. North America continues to lead due to its advanced healthcare ecosystem, while Asia Pacific emerges as the new growth frontier, driven by demographic trends and healthcare modernization.

Looking ahead, the integration of biotechnology, digital health, and precision medicine will redefine the standards of osteoarthritis management. As regenerative and disease-modifying therapies move closer to commercial reality, the future of osteoarthritis care promises not only improved pain relief but also genuine restoration of mobility and quality of life for millions worldwide.

Read More Related Reports:

Oculoplastic Surgery Market https://www.persistencemarketresearch.com/market-research/oculoplastic-surgery-market.asp
Neonatal Toxicology Market https://www.persistencemarketresearch.com/market-research/neonatal-toxicology-market.asp
Ovarian Cancer Diagnostics Market https://www.persistencemarketresearch.com/market-research/ovarian-cancer-diagnostics-market.asp
Pediatric Cancer Biomarkers Market https://www.persistencemarketresearch.com/market-research/pediatric-cancer-biomarker-market.asp
Specimen Collection Cards Market https://www.persistencemarketresearch.com/market-research/specimen-collection-cards-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.